The Charity Medicines Access Coalition works to find long-term solutions to the challenges that can delay or prevent patient access to new and innovative medicines.

The coalition is chaired by Alzheimer’s Research UK and brings together more than 10 health charities. We represent millions of people across a range of disease areas and are major funders of research.

Working together, we strengthen charity voices in debates around new medicines, focusing our actions and recommendations on:

  • Identifying and supporting ways to improve the adoption of new medicines into the NHS in England, with the financial sustainability of the NHS being critical.
  • Acting as an honest broker and critical friend to key decision-makers to remove current and potential barriers that are preventing people accessing much-needed new treatment options.
  • Ensuring people with lived experience are at the heart of regulatory and approval processes when decisions are made about the value and affordability of new medicines.

To help support discussions around new medicines, the coalition has established relationships with decision-makers across the healthcare system. This includes NHS England, the National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA), the Department of Health and Social Care (DHSC) and the Association of the British Pharmaceutical Industry (ABPI).

Our open letter to Government and the ABPI

We call on stakeholders involved in the VPAS negotiations to involve charitable organisations in the upcoming review about the future of the scheme.

What is the power in collaboration?

At Alzheimer’s Research UK, we pride ourselves on being collaborative in how we work with each other and other organisations to drive change.

Coalition members